Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial
Clemmons DR, Miller S, Mamputu JC (2017). PLOS ONE.
Summary
A safety trial addressing the concern that growth hormone and related compounds worsen insulin sensitivity. Fifty-three people with type 2 diabetes were randomised to placebo or one of two tesamorelin groups for 12 weeks. Insulin response to an oral glucose load did not differ significantly between groups, and neither did fasting glucose, HbA1c or overall diabetes control at 12 weeks. Total and non-HDL cholesterol fell in the higher tesamorelin group relative to placebo. No participant stopped the study because diabetes control was lost. Small and short.